Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
|Articles|April 15, 2015
Mouvex Announces Product Recovery Cost Savings Calculator
Mouvex Announces Product Recovery Cost Savings Calculator Mouvex announces its Product Recovery Cost Savings Calculator to determine waste reduction and cost savings with the use of Mouvex Eccentric Disc Pumps.
Advertisement
Mouvex, part of PSG, a Dover Company, announced the release of its Product Recovery Cost Savings Calculator.
“Far too often, expensive raw materials or saleable finished products are just washed out and flushed down the drain. This product loss is often viewed as nothing more than an acceptable ‘cost of doing business’ for many hygienic manufacturers,” said Wallace Wittkoff, director of global segments and key account management, PSG, in a press release.
Mouvex eccentric disc pumps have no mechanical seals, eliminating the risk of leakage. The pumps offer clean-in-place and sanitize-in-place, dry-run and self-priming capabilities, and can recover 60% to 80% of product from transfer lines.
Source:
Advertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Advertisement
Advertisement